Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
An analysis of short-term activity ratios reveals a period of expanding operational cycles followed by a phase of relative stabilization. The primary driver of volatility throughout the observed timeframe was inventory management, while receivables remained consistently stable, and payables experienced strategic fluctuations.
- Inventory Management Efficiency
- A downward trend in inventory turnover is observed from July 2021 (2.47) reaching a trough in July 2023 (1.91). This decline is mirrored by the average inventory processing period, which extended from 148 days to a peak of 191 days. From late 2023 through July 2026, a moderate recovery occurred, with the turnover ratio stabilizing around 2.11 and the processing period normalizing to 173 days.
- Receivables and Collections
- Receivables turnover remained remarkably stable throughout the period, fluctuating within a narrow range between 5.21 and 5.91. Consequently, the average receivable collection period showed minimal variance, generally oscillating between 62 and 71 days. This indicates a highly consistent and disciplined approach to credit management and collections.
- Payables and Liquidity Strategy
- Payables turnover showed more volatility, declining from 5.67 in July 2021 to a low of 4.03 in April 2023, before recovering to 4.87 by July 2026. The average payables payment period expanded from 64 days to a maximum of 91 days in April 2023, suggesting a temporary extension of payment terms to suppliers to preserve cash flow, followed by a return to a more stable payment cycle of approximately 75 days.
- Operational Cycle and Cash Conversion
- The operating cycle experienced a significant expansion, rising from 211 days in July 2021 to a peak of 260 days in January 2023, primarily driven by the slowing of inventory turnover. The cash conversion cycle followed a similar trajectory, increasing from 147 days to 189 days by January 2024. In the final quarters of the analysis, the cash conversion cycle contracted to 160 days, indicating improved efficiency in converting resources into cash.
- Working Capital Utilization
- Working capital turnover demonstrated an overall upward trend, increasing from 2.15 in July 2021 to 2.98 in July 2026. Despite some volatility in 2022, the general increase suggests an improved ability to generate revenue relative to the investment in net working capital.
AI Ask an analyst for more
Turnover Ratios
Average No. Days
Inventory Turnover
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Cost of products sold, excluding amortization of intangible assets | 3,416) | 3,398) | 3,261) | 3,061) | 3,001) | 3,146) | 2,779) | 2,946) | 2,761) | 3,045) | 2,782) | 2,761) | 2,628) | 2,979) | 2,689) | 2,535) | 2,516) | 2,591) | 2,459) | 2,497) | 2,598) | |||||||
| Inventories | 6,215) | 5,951) | 6,309) | 6,156) | 5,886) | 5,476) | 5,610) | 5,479) | 5,414) | 5,217) | 5,726) | 5,754) | 5,668) | 5,293) | 5,375) | 5,055) | 4,809) | 4,616) | 4,514) | 4,349) | 4,288) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||
| Inventory turnover1 | 2.11 | 2.14 | 1.98 | 1.95 | 2.02 | 2.12 | 2.06 | 2.11 | 2.10 | 2.15 | 1.95 | 1.92 | 1.91 | 2.03 | 1.92 | 2.00 | 2.09 | 2.20 | 2.26 | 2.38 | 2.47 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 2.76 | 2.82 | 2.98 | 2.88 | 2.73 | 2.82 | 3.02 | 2.69 | 2.67 | 2.65 | 2.74 | 2.71 | 2.62 | 2.77 | 3.10 | 3.37 | 3.24 | 3.36 | |||||||
| Intuitive Surgical Inc. | — | — | — | 1.81 | 1.83 | 1.86 | 1.81 | 1.83 | 1.85 | 1.83 | 1.75 | 1.81 | 1.89 | 1.96 | 1.99 | 2.21 | 2.25 | 2.27 | 2.36 | 2.62 | 2.82 | |||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Inventory turnover
= (Cost of products sold, excluding amortization of intangible assetsQ1 2027
+ Cost of products sold, excluding amortization of intangible assetsQ4 2026
+ Cost of products sold, excluding amortization of intangible assetsQ3 2026
+ Cost of products sold, excluding amortization of intangible assetsQ2 2026)
÷ Inventories
= (3,416 + 3,398 + 3,261 + 3,061)
÷ 6,215 = 2.11
2 Click competitor name to see calculations.
A long-term decline in inventory turnover efficiency is observed from July 2021 through July 2026. While the cost of products sold exhibited a general upward trajectory, the growth in inventory levels occurred at a pace that outstripped the growth of costs for a significant portion of the observed period, resulting in a lower overall turnover ratio.
- Inventory Turnover Trends
- The turnover ratio experienced a steady contraction from a peak of 2.47 in July 2021 to a low of 1.91 in July 2023. This downward trajectory indicates a slowing of inventory movement relative to the cost of goods sold during the first two years of the period.
- Relationship Between Cost of Products Sold and Inventory Levels
- Cost of products sold increased from 2,598 million USD in July 2021 to 3,416 million USD by July 2026. Concurrently, inventory levels rose from 4,288 million USD to 6,215 million USD. The disproportionate increase in inventory holdings between 2021 and 2023 acted as the primary driver for the reduction in the turnover ratio.
- Period of Stabilization
- From January 2024 through July 2026, the inventory turnover ratio entered a phase of relative stabilization, fluctuating within a range between 1.95 and 2.15. This suggests a shift toward more consistent inventory management after the initial period of efficiency loss.
AI Ask an analyst for more
Receivables Turnover
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net sales | 9,756) | 9,808) | 9,017) | 8,961) | 8,578) | 8,927) | 8,292) | 8,403) | 7,915) | 8,589) | 8,089) | 7,984) | 7,702) | 8,544) | 7,727) | 7,585) | 7,371) | 8,089) | 7,763) | 7,847) | 7,987) | |||||||
| Accounts receivable, less allowances and credit losses | 6,357) | 6,643) | 6,359) | 6,389) | 6,263) | 6,515) | 6,115) | 6,260) | 6,011) | 6,128) | 5,968) | 5,934) | 5,806) | 5,998) | 5,887) | 5,626) | 5,308) | 5,551) | 5,446) | 5,493) | 5,431) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||
| Receivables turnover1 | 5.91 | 5.47 | 5.58 | 5.44 | 5.46 | 5.15 | 5.43 | 5.27 | 5.42 | 5.28 | 5.42 | 5.39 | 5.44 | 5.21 | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 5.42 | 5.50 | 5.59 | 5.39 | 5.41 | 5.78 | 6.06 | 5.85 | 5.94 | 6.11 | 6.11 | 6.15 | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | |||||||
| Elevance Health Inc. | — | — | — | 14.99 | 14.30 | 16.34 | 16.80 | 14.83 | 14.42 | 18.00 | 19.84 | 17.60 | 15.98 | 18.08 | 17.93 | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | |||||||
| Intuitive Surgical Inc. | — | — | — | 6.59 | 6.63 | 6.59 | 7.63 | 7.21 | 7.13 | 6.82 | 6.82 | 6.83 | 6.49 | 6.30 | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | |||||||
| UnitedHealth Group Inc. | — | — | — | 20.67 | 16.76 | 19.27 | 18.98 | 17.29 | 15.03 | 17.66 | 19.43 | 16.49 | 13.80 | 17.27 | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | |||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Receivables turnover
= (Net salesQ1 2027
+ Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026)
÷ Accounts receivable, less allowances and credit losses
= (9,756 + 9,808 + 9,017 + 8,961)
÷ 6,357 = 5.91
2 Click competitor name to see calculations.
The financial trajectory from July 2021 through July 2026 is characterized by steady growth in top-line revenue and a corresponding increase in outstanding receivables, resulting in a receivables turnover ratio that remained largely resilient despite a period of moderate volatility.
- Revenue and Receivables Growth
- Net sales exhibited a general upward trend, rising from 7,987 million US dollars in July 2021 to 9,756 million US dollars by July 2026. In parallel, accounts receivable, less allowances and credit losses, increased from 5,431 million US dollars to 6,357 million US dollars. The expansion of receivables suggests that credit extension grew in alignment with the broader growth in sales volume.
- Analysis of Receivables Turnover Trends
- The receivables turnover ratio experienced three distinct phases. From July 2021 to July 2022, the ratio remained stable, fluctuating within a narrow band between 5.71 and 5.85. A subsequent decline was observed between October 2022 and April 2023, with the ratio reaching a period low of 5.21. This downward movement indicates a temporary reduction in collection efficiency relative to sales growth during that interval.
- Stabilization and Recovery
- Following the low point in early 2023, the turnover ratio entered a period of stabilization between July 2023 and January 2025, generally oscillating between 5.15 and 5.46. A notable recovery is evident in the final quarters of the analysis, culminating in a ratio of 5.91 by July 2026. This peak represents the highest level of turnover efficiency in the observed period, suggesting a successful optimization of credit collections or a shift toward more favorable customer payment terms.
AI Ask an analyst for more
Payables Turnover
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Cost of products sold, excluding amortization of intangible assets | 3,416) | 3,398) | 3,261) | 3,061) | 3,001) | 3,146) | 2,779) | 2,946) | 2,761) | 3,045) | 2,782) | 2,761) | 2,628) | 2,979) | 2,689) | 2,535) | 2,516) | 2,591) | 2,459) | 2,497) | 2,598) | |||||||
| Accounts payable | 2,695) | 2,644) | 2,569) | 2,581) | 2,555) | 2,449) | 2,286) | 2,376) | 2,291) | 2,410) | 1,992) | 2,174) | 2,239) | 2,662) | 2,209) | 2,198) | 2,180) | 2,276) | 1,985) | 1,917) | 1,864) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||
| Payables turnover1 | 4.87 | 4.81 | 4.85 | 4.64 | 4.65 | 4.75 | 5.04 | 4.85 | 4.95 | 4.65 | 5.60 | 5.09 | 4.84 | 4.03 | 4.68 | 4.60 | 4.62 | 4.46 | 5.14 | 5.41 | 5.67 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 4.22 | 4.22 | 4.56 | 4.69 | 4.40 | 4.44 | 4.46 | 4.54 | 4.42 | 4.33 | 4.19 | 4.55 | 4.28 | 4.44 | 4.15 | 4.67 | 4.25 | 4.02 | |||||||
| Elevance Health Inc. | — | — | — | 8.06 | 8.06 | 8.68 | 8.38 | 8.07 | 7.87 | 8.10 | 8.17 | 8.09 | 7.54 | 7.72 | 7.61 | 7.54 | 7.57 | 7.47 | 7.48 | 7.35 | 7.28 | |||||||
| Intuitive Surgical Inc. | — | — | — | 13.26 | 10.71 | 13.42 | 11.10 | 11.44 | 10.39 | 14.05 | 11.88 | 12.91 | 12.64 | 12.69 | 11.66 | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | |||||||
| UnitedHealth Group Inc. | — | — | — | 7.98 | 7.92 | 7.98 | 7.44 | 7.42 | 7.32 | 7.72 | 7.64 | 7.77 | 7.28 | 7.47 | 7.11 | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | |||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Payables turnover
= (Cost of products sold, excluding amortization of intangible assetsQ1 2027
+ Cost of products sold, excluding amortization of intangible assetsQ4 2026
+ Cost of products sold, excluding amortization of intangible assetsQ3 2026
+ Cost of products sold, excluding amortization of intangible assetsQ2 2026)
÷ Accounts payable
= (3,416 + 3,398 + 3,261 + 3,061)
÷ 2,695 = 4.87
2 Click competitor name to see calculations.
Analysis of short-term operating activity reveals a general expansion in both the cost of products sold and the balance of accounts payable over the observed period. The cost of products sold increased from 2,598 million US dollars in July 2021 to 3,416 million US dollars by July 2026. Parallel to this, accounts payable rose from 1,864 million US dollars to 2,695 million US dollars, reflecting an increase in the absolute volume of obligations to suppliers as operational scale grew.
- Payables Turnover Trajectory
- The payables turnover ratio exhibited a notable downward trend during the initial phase of the period, falling from a high of 5.67 in July 2021 to a minimum of 4.03 in April 2023. This decline indicates a deceleration in the frequency with which supplier obligations were settled, effectively extending the average payment period.
- Ratio Stabilization and Normalization
- Following the low point in early 2023, the turnover ratio entered a period of relative stability. From July 2023 through July 2026, the ratio consistently fluctuated between 4.64 and 5.60, ending the period at 4.87. This stabilization suggests the establishment of a consistent credit management strategy and a normalized relationship between procurement costs and payment cycles.
- Operational Scale and Working Capital Management
- While the cost of products sold grew substantially over the five-year period, the payables turnover ratio did not revert to the higher levels observed in 2021. This suggests a strategic decision to maintain higher levels of accounts payable relative to the cost of sales, which can serve to optimize cash flow by utilizing supplier credit to support increased operational activity.
AI Ask an analyst for more
Working Capital Turnover
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Current assets | 24,390) | 24,787) | 24,071) | 23,996) | 23,223) | 23,814) | 22,513) | 22,438) | 21,947) | 21,935) | 22,513) | 22,081) | 21,869) | 21,675) | 25,364) | 25,398) | 22,135) | 23,059) | 23,303) | 22,731) | 22,434) | |||||||
| Less: Current liabilities | 11,799) | 11,658) | 9,495) | 9,935) | 11,530) | 12,879) | 11,840) | 12,195) | 10,287) | 10,789) | 9,793) | 9,659) | 9,047) | 9,051) | 14,422) | 14,465) | 14,049) | 12,394) | 8,927) | 7,803) | 7,764) | |||||||
| Working capital | 12,591) | 13,129) | 14,576) | 14,061) | 11,693) | 10,935) | 10,673) | 10,243) | 11,660) | 11,146) | 12,720) | 12,422) | 12,822) | 12,624) | 10,942) | 10,933) | 8,086) | 10,665) | 14,376) | 14,928) | 14,670) | |||||||
| Net sales | 9,756) | 9,808) | 9,017) | 8,961) | 8,578) | 8,927) | 8,292) | 8,403) | 7,915) | 8,589) | 8,089) | 7,984) | 7,702) | 8,544) | 7,727) | 7,585) | 7,371) | 8,089) | 7,763) | 7,847) | 7,987) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||
| Working capital turnover1 | 2.98 | 2.77 | 2.43 | 2.47 | 2.92 | 3.07 | 3.11 | 3.22 | 2.79 | 2.90 | 2.54 | 2.57 | 2.46 | 2.47 | 2.81 | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 6.95 | 6.33 | 4.67 | 4.27 | 3.91 | 4.17 | 4.42 | 4.63 | 4.35 | 4.83 | 4.54 | 4.15 | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | |||||||
| Elevance Health Inc. | — | — | — | 7.19 | 7.59 | 7.50 | 7.00 | 7.96 | 8.11 | 7.85 | 6.87 | 6.92 | 8.59 | 7.83 | 7.92 | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | |||||||
| Intuitive Surgical Inc. | — | — | — | 1.45 | 1.53 | 1.29 | 1.43 | 1.30 | 1.42 | 1.56 | 1.42 | 1.23 | 1.17 | 1.14 | 0.95 | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | |||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Working capital turnover
= (Net salesQ1 2027
+ Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026)
÷ Working capital
= (9,756 + 9,808 + 9,017 + 8,961)
÷ 12,591 = 2.98
2 Click competitor name to see calculations.
The analysis of working capital turnover reveals a period of significant fluctuation followed by a phase of relative stabilization. While net sales have demonstrated a gradual and consistent upward trajectory over the analyzed period, the efficiency of working capital utilization has been primarily driven by variances in the working capital base rather than sales growth alone.
- Working Capital Turnover Volatility
- A notable peak in efficiency occurred in July 2022, where the turnover ratio reached 3.84. This surge was primarily attributed to a sharp contraction in working capital, which fell to its lowest point of $8,086 million. Following this peak, the ratio corrected and generally remained between 2.40 and 3.22 through the subsequent quarters.
- Revenue Growth Dynamics
- Net sales exhibited a steady increase, rising from $7,987 million in July 2021 to a peak of $9,808 million in April 2026. This sustained growth suggests a strengthening top-line performance, although the impact on the turnover ratio was often moderated by simultaneous increases in the working capital requirements.
- Working Capital Trends
- The working capital balance showed a cyclical pattern, starting at $14,670 million, dipping significantly in mid-2022, and recovering to a peak of $14,576 million by January 2026. The recent decline to $12,591 million by July 2026, coupled with maintained high sales levels, resulted in a turnover ratio of 2.98, indicating a return to higher operational efficiency.
- Efficiency Correlation
- An inverse relationship is observed between the total working capital held and the turnover ratio. The most efficient periods of operation coincide with lean working capital levels, whereas periods of capital accumulation, such as the trend observed between October 2024 and January 2026, saw the turnover ratio decline toward 2.43.
AI Ask an analyst for more
Average Inventory Processing Period
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||
| Inventory turnover | 2.11 | 2.14 | 1.98 | 1.95 | 2.02 | 2.12 | 2.06 | 2.11 | 2.10 | 2.15 | 1.95 | 1.92 | 1.91 | 2.03 | 1.92 | 2.00 | 2.09 | 2.20 | 2.26 | 2.38 | 2.47 | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||
| Average inventory processing period1 | 173 | 171 | 185 | 187 | 181 | 172 | 178 | 173 | 174 | 170 | 187 | 190 | 191 | 180 | 190 | 183 | 174 | 166 | 161 | 153 | 148 | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 132 | 129 | 123 | 127 | 134 | 130 | 121 | 136 | 136 | 138 | 133 | 135 | 139 | 132 | 118 | 108 | 113 | 109 | |||||||
| Intuitive Surgical Inc. | — | — | — | 201 | 199 | 196 | 201 | 199 | 198 | 200 | 208 | 201 | 193 | 186 | 183 | 166 | 162 | 161 | 155 | 139 | 130 | |||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.11 = 173
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a distinct two-phase trend in inventory management efficiency from July 2021 through July 2026. An initial period of declining efficiency is followed by a phase of relative stabilization and moderate recovery.
- Inventory Turnover Dynamics
- A consistent decline in the inventory turnover ratio is observed between July 2021 and January 2023, during which the ratio fell from 2.47 to 1.92. Following this decline, the ratio entered a period of fluctuation with a moderate recovery, reaching a localized peak of 2.15 in January 2024. Through 2025 and 2026, the turnover ratio remained relatively stable, oscillating within a range of 1.95 to 2.14.
- Average Inventory Processing Period
- The timeframe required to process inventory experienced a steady expansion from 148 days in July 2021 to a peak of 191 days in July 2023. This expansion indicates a slowdown in inventory movement. A corrective shift occurred in early 2024, where the processing period dropped to 170 days. For the remainder of the analyzed period ending July 2026, the processing period remained range-bound, fluctuating between 171 and 187 days.
- Operational Efficiency Correlation
- A strong inverse correlation is evident between the turnover ratio and the processing period. The peak in processing days in July 2023 corresponds with the lowest turnover ratio of 1.91, marking the point of lowest operational efficiency. The subsequent improvement in the turnover ratio throughout 2024 and 2026 aligns with the reduction in the average days inventory was held, suggesting a strategic adjustment to optimize stock levels and improve liquidity.
AI Ask an analyst for more
Average Receivable Collection Period
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||
| Receivables turnover | 5.91 | 5.47 | 5.58 | 5.44 | 5.46 | 5.15 | 5.43 | 5.27 | 5.42 | 5.28 | 5.42 | 5.39 | 5.44 | 5.21 | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||
| Average receivable collection period1 | 62 | 67 | 65 | 67 | 67 | 71 | 67 | 69 | 67 | 69 | 67 | 68 | 67 | 70 | 70 | 67 | 62 | 64 | 63 | 63 | 63 | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 67 | 66 | 65 | 68 | 67 | 63 | 60 | 62 | 61 | 60 | 60 | 59 | 56 | 53 | 52 | 52 | 58 | 59 | |||||||
| Elevance Health Inc. | — | — | — | 24 | 26 | 22 | 22 | 25 | 25 | 20 | 18 | 21 | 23 | 20 | 20 | 19 | 22 | 19 | 19 | 19 | 22 | |||||||
| Intuitive Surgical Inc. | — | — | — | 55 | 55 | 55 | 48 | 51 | 51 | 54 | 53 | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | |||||||
| UnitedHealth Group Inc. | — | — | — | 18 | 22 | 19 | 19 | 21 | 24 | 21 | 19 | 22 | 26 | 21 | 21 | 19 | 25 | 20 | 20 | 22 | 23 | |||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.91 = 62
2 Click competitor name to see calculations.
An analysis of the operating activity ratios reveals a period of stability followed by a moderate increase in the time required to collect receivables, concluding with a return to historical efficiency levels by the end of the observed period.
- Receivables Turnover Trends
- The receivables turnover ratio remained relatively stable between 5.71 and 5.85 during the first year of analysis. A gradual decline was observed starting in late 2022, with the ratio reaching a low of 5.15 in January 2025. Following this trough, a recovery trend emerged, culminating in a peak turnover ratio of 5.91 by July 2026, representing the highest efficiency level recorded in the dataset.
- Average Receivable Collection Period
- The collection period began at 63 days and remained consistent until July 2022. A shift toward slower collections occurred in 2023, with the period extending to 70 days by January and April of that year. The collection period fluctuated between 67 and 69 days for several subsequent quarters, reaching a maximum of 71 days in January 2025. A notable improvement in collection speed occurred toward the end of the period, with the duration dropping to 62 days by July 2026.
- Operational Efficiency Correlation
- A consistent inverse correlation exists between the receivables turnover ratio and the average collection period. The period of lowest turnover between January 2023 and April 2024 corresponds directly with the increase in the collection period to 67-70 days. The efficiency peak in July 2026, characterized by a turnover ratio of 5.91, aligns with the minimum collection period of 62 days, indicating an optimization of the credit-to-cash cycle.
The overall trajectory indicates that while there was a multi-year period of decelerated receivable collections peaking in early 2025, the operational activity has since reverted to, and slightly improved upon, the efficiency levels observed at the start of the analysis period.
AI Ask an analyst for more
Operating Cycle
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||
| Average inventory processing period | 173 | 171 | 185 | 187 | 181 | 172 | 178 | 173 | 174 | 170 | 187 | 190 | 191 | 180 | 190 | 183 | 174 | 166 | 161 | 153 | 148 | |||||||
| Average receivable collection period | 62 | 67 | 65 | 67 | 67 | 71 | 67 | 69 | 67 | 69 | 67 | 68 | 67 | 70 | 70 | 67 | 62 | 64 | 63 | 63 | 63 | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||
| Operating cycle1 | 235 | 238 | 250 | 254 | 248 | 243 | 245 | 242 | 241 | 239 | 254 | 258 | 258 | 250 | 260 | 250 | 236 | 230 | 224 | 216 | 211 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 199 | 195 | 188 | 195 | 201 | 193 | 181 | 198 | 197 | 198 | 193 | 194 | 195 | 185 | 170 | 160 | 171 | 168 | |||||||
| Intuitive Surgical Inc. | — | — | — | 256 | 254 | 251 | 249 | 250 | 249 | 254 | 261 | 254 | 249 | 244 | 234 | 216 | 215 | 216 | 206 | 190 | 186 | |||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 173 + 62 = 235
2 Click competitor name to see calculations.
The operating cycle exhibits a general upward trend from mid-2021 through early 2023, followed by a period of relative stabilization with moderate volatility. The overall extension of the cycle is primarily driven by increases in inventory processing time rather than changes in receivable collection efficiency.
- Average Inventory Processing Period
- A significant expansion is observed in the time required to process inventory, rising from 148 days in July 2021 to a peak of 191 days in July 2023. Following this peak, the period fluctuates between 170 and 187 days. The most recent data indicates a slight stabilization around 173 days as of July 2026, though this remains substantially higher than the initial 2021 levels, suggesting a structural shift in inventory holding patterns.
- Average Receivable Collection Period
- The collection period demonstrates remarkable stability throughout the analyzed timeframe. Values remain within a narrow corridor, fluctuating between a minimum of 62 days and a maximum of 71 days. The consistency of this metric indicates that credit policies and collection efficiencies have remained constant regardless of the volatility seen in other components of the operating cycle.
- Operating Cycle Synthesis
- The total operating cycle increased from 211 days in July 2021 to a peak of 260 days in January 2023. Because the receivable collection period remained flat, the 49-day expansion observed during the growth phase is attributable almost exclusively to the average inventory processing period. In the final quarters of the analysis, the cycle shows a moderate contraction, ending at 235 days in July 2026, reflecting a slight improvement in inventory turnover relative to the 2023 peaks.
AI Ask an analyst for more
Average Payables Payment Period
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||
| Payables turnover | 4.87 | 4.81 | 4.85 | 4.64 | 4.65 | 4.75 | 5.04 | 4.85 | 4.95 | 4.65 | 5.60 | 5.09 | 4.84 | 4.03 | 4.68 | 4.60 | 4.62 | 4.46 | 5.14 | 5.41 | 5.67 | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||
| Average payables payment period1 | 75 | 76 | 75 | 79 | 79 | 77 | 72 | 75 | 74 | 78 | 65 | 72 | 75 | 91 | 78 | 79 | 79 | 82 | 71 | 67 | 64 | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 87 | 87 | 80 | 78 | 83 | 82 | 82 | 80 | 83 | 84 | 87 | 80 | 85 | 82 | 88 | 78 | 86 | 91 | |||||||
| Elevance Health Inc. | — | — | — | 45 | 45 | 42 | 44 | 45 | 46 | 45 | 45 | 45 | 48 | 47 | 48 | 48 | 48 | 49 | 49 | 50 | 50 | |||||||
| Intuitive Surgical Inc. | — | — | — | 28 | 34 | 27 | 33 | 32 | 35 | 26 | 31 | 28 | 29 | 29 | 31 | 33 | 28 | 26 | 30 | 29 | 25 | |||||||
| UnitedHealth Group Inc. | — | — | — | 46 | 46 | 46 | 49 | 49 | 50 | 47 | 48 | 47 | 50 | 49 | 51 | 52 | 53 | 50 | 52 | 53 | 54 | |||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 4.87 = 75
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a period of volatility in the management of accounts payable between mid-2021 and early 2024, followed by a phase of relative stability in the payment cycle.
- Payables Turnover Trends
- A gradual decline in the turnover ratio was observed from a high of 5.67 in July 2021 to a minimum of 4.03 in April 2023. This downward trend indicates a reduction in the frequency with which supplier obligations were settled. Following this trough, the ratio recovered and maintained a consistent range between 4.64 and 4.87 from July 2024 through July 2026, suggesting a stabilized operational cadence.
- Average Payables Payment Period
- The payment period exhibited a significant expansion during the first two years of the period, rising from 64 days in July 2021 to a peak of 91 days in April 2023. A sharp correction occurred thereafter, with the period dropping to 65 days by January 2024. Since mid-2024, the payment duration has normalized, fluctuating narrowly between 72 and 79 days, indicating a consistent approach to liability management.
- Working Capital Implications
- The expansion of the payment period up to 91 days suggests a period of aggressive working capital optimization, where the extension of payment terms served to preserve cash liquidity. The subsequent stabilization around the 75-day mark indicates a shift toward a sustainable equilibrium between liquidity preservation and the maintenance of supplier relationships.
AI Ask an analyst for more
Cash Conversion Cycle
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||
| Average inventory processing period | 173 | 171 | 185 | 187 | 181 | 172 | 178 | 173 | 174 | 170 | 187 | 190 | 191 | 180 | 190 | 183 | 174 | 166 | 161 | 153 | 148 | |||||||
| Average receivable collection period | 62 | 67 | 65 | 67 | 67 | 71 | 67 | 69 | 67 | 69 | 67 | 68 | 67 | 70 | 70 | 67 | 62 | 64 | 63 | 63 | 63 | |||||||
| Average payables payment period | 75 | 76 | 75 | 79 | 79 | 77 | 72 | 75 | 74 | 78 | 65 | 72 | 75 | 91 | 78 | 79 | 79 | 82 | 71 | 67 | 64 | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||
| Cash conversion cycle1 | 160 | 162 | 175 | 175 | 169 | 166 | 173 | 167 | 167 | 161 | 189 | 186 | 183 | 159 | 182 | 171 | 157 | 148 | 153 | 149 | 147 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 112 | 108 | 108 | 117 | 118 | 111 | 99 | 118 | 114 | 114 | 106 | 114 | 110 | 103 | 82 | 82 | 85 | 77 | |||||||
| Intuitive Surgical Inc. | — | — | — | 228 | 220 | 224 | 216 | 218 | 214 | 228 | 230 | 226 | 220 | 215 | 203 | 183 | 187 | 190 | 176 | 161 | 161 | |||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 173 + 62 – 75 = 160
2 Click competitor name to see calculations.
The cash conversion cycle exhibits a general upward trend from July 2021 through early 2024, indicating a lengthening of the time required to convert resource inputs into cash flows. This increase is primarily driven by a significant extension in the inventory processing period, which was partially offset by an extension in payables payment terms. Following a peak in January 2024, the cycle has shown a moderate trend toward stabilization and slight reduction.
- Average Inventory Processing Period
- A sustained increase is observed from July 2021, where the period stood at 148 days, peaking at 191 days in July 2023. This indicates a slowing of inventory turnover during this phase. Subsequently, the period experienced a correction, dropping to 170 days by April 2024, before stabilizing between 171 and 187 days through July 2026.
- Average Receivable Collection Period
- The collection of receivables remained remarkably stable throughout the analyzed period. The duration fluctuated within a narrow range of 62 to 71 days, suggesting consistent credit policies and efficient collection processes that were not significantly impacted by the volatility seen in other components of the working capital cycle.
- Average Payables Payment Period
- Payment terms to suppliers were extended from 64 days in July 2021 to a peak of 91 days in April 2023. This extension served as a strategic buffer to mitigate the cash flow pressure caused by rising inventory levels. In the latter half of the period, the payment period normalized, fluctuating between 65 and 79 days.
- Cash Conversion Cycle
- The overall cash conversion cycle rose from 147 days in July 2021 to a maximum of 189 days in January 2024. The expansion was almost entirely attributable to the increase in the inventory processing period. A reduction is noted starting in April 2024, with the cycle closing at 160 days in July 2026, representing a partial recovery in operational efficiency compared to the 2023-2024 peak, though remaining higher than the 2021 baseline.
AI Ask an analyst for more